Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Study of ADR-002K in Heart Failure Patients With Ischemic Heart Disease Undergoing CABG
jRCT2053250022Recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ADR-002K in heart failure (HF) and coronary arteriosclerosis, sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Heart Failure Event. Started May 2025; status: recruiting.
02
Drugs
ADR-002K
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2053250022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053250022.